DOCSLIB.ORG

Characterization of Uracil Dna Glycosylase As a Therapeutic Target for Sensitization of Floxuridine in Cancer with P53 Mutation Or Deficiency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Characterization of Uracil Dna Glycosylase As a Therapeutic Target for Sensitization of Floxuridine in Cancer with P53 Mutation Or Deficiency CHARACTERIZATION OF URACIL DNA GLYCOSYLASE AS A THERAPEUTIC TARGET FOR SENSITIZATION OF FLOXURIDINE IN CANCER WITH P53 MUTATION OR DEFICIENCY by YAN YAN Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Thesis Advisor: Dr. Stanton L. Gerson, M.D. Department of Pharmacology CASE WESTERN RESERVE UNIVERSITY August, 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Yan Yan candidate for the degree of Doctor of Philosophy *. Committee Chair Youwei Zhang Committee Member Stanton Gerson Committee Member Maria Hatzoglou Committee Member Derek Taylor Committee Member Alexandru Almasan Date of defense April 24th, 2017 *We also certify that written approval has been obtained for any proprietary material contained therein. Page | ii TABLE OF CONTENTS Table of Contents…………………………….…………………………………………...iii List of Tables……………………………………….………………….…………………vii List of Figures…………………….……………………………….…….………………viii Acknowledgements………………………………………………………….……………xi List of Abbreviations…………………………………………………….……….………xii Abstract……………………………………………………………………………………1 Chapter 1. Introduction……………………………………………………………….……4 1.1 TS inhibitors and the directed effects………………………………………………4 1.1.1 TS inhibition by fluoropyrimidines………………………...…………….….6 1.1.2 TS inhibition by antifolates…………………………………………...……...8 1.1.3 Thymineless death…………………………………………………………...9 1.2 Impact of BER repair pathway on TS inhibitors……………...…….…………….10 1.2.1 Uracil and 5-FU excision by DNA glycosylases……………………………13 1.2.2 Downstream components of BER………………………………….……….16 1.3 Molecular determinants of response to TS inhibitors…………………………….19 1.3.1 Thymidylate synthase………………………………………………………19 1.3.2 p53………………………………………………………………………….20 1.3.3 dUTPase……………………………………………………………………22 1.3.4 Other DNA repair pathways…….……………………….…….…….….….24 Page | iii 1.4 Tumor suppressor p53 and its regulation…………………………………………27 1.5 The role of p53 in apoptosis…………………………………………….………...29 1.6 p53 germline and somatic mutations…………….………………….…………...30 1.7 Mutant p53 gain of functions and their link to chemoresistance………....……….31 1.8 Statement of objectives…………………………………………………………...35 Chapter 2. Inhibition of uracil DNA glycosylase (UDG) sensitizes cancer cells to 5- fluorodeoxyuridine through replication fork collapse-induced DNA damage……........…38 2.1 Abstract…………………………………….……………...………………….….39 2.2 Introduction……………………………………………….……………………...40 2.3 Materials and methods………………….………………………………………...42 2.4 Results……………………………………………………………………………48 2.4.1 UDG removes uracil and 5-FU incorporated into DNA following 5-FdU treatment…………………………………………………………………………48 2.4.2 Loss of UDG enhances cytotoxicity of 5-FdU in cancer cells......................50 2.4.3 Thymidine treatment after 5-FdU exposure cannot fully rescue the enhanced cytotoxicity in UDG depleted cells due to the retention of genomic uracil and 5- FU.……………………………………………………………………………….51 2.4.4 UDG depletion leads to cell cycle arrest at late G1 and early S phase by 5- FdU…....................................................................................................................52 Page | iv 2.4.5 Loss of UDG inhibits DNA replication progression in response to 5-FdU treatment…………………………………………………………………………53 2.4.6 DNA damage persists in UDG depleted cells and is not due to apoptosis by 5-FdU treatment………………………………………………………………….54 2.5 Discussion………………………………….…………………………………….56 Chapter 3. Knockdown of uracil DNA glycosylase selectively re-sensitizes p53 mutant and deficient human cancer cells to 5-fluorodeoxyuridine………………………….…....72 3.1 Abstract…………………………………….……………...………………….….73 3.2 Introduction………………………………………………………………………74 3.3 Materials and methods………………….………………………………………...77 3.4 Results……………………………………………………………………………80 3.4.1 p53 mutation or deficiency affords 5-FdU resistance among different types of cancer cells……………………………………………………………….……80 3.4.2 UDG depletion sensitizes cancer cells with p53 mutation or deficiency to 5- FdU exposure…………………………………………………………………….81 3.4.3 5-FdU resistance in p53 knockout (KO) or knockdown (KD) cells is reversed by UDG depletion………………………………………………………….…….82 3.4.4 UDG depletion selectively sensitizes p53 KO cancer cells to pemetrexed and 5-FU.......................................................................................................................83 Page | v 3.4.5 5-FdU activates cell death in p53 KO cancer cells with depleted UDG………….………….……………………………………………………….84 3.5 Discussion……………………………….……………………………………….85 Chapter 4. Conclusions and future directions…………………………………………...101 4.1 Conclusions…………………….……………………………………………….101 4.2 Future directions………………………………………………………………...103 4.2.1 Evaluation of the interplay between p53 and thymidylate synthase (TS) on cytotoxicity of TS inhibitors…………………………………………………….103 4.2.2 Characterization of the effect of other glycosylases (SMUG1, TDG, MBD4) in processing genomic uracil and 5-FU induced by 5-fluorodeoxyuridine...…....106 4.2.3 Exploitation of DNA damage response signaling as a target to achieve ‘synthetic sickness or lethality’ with UDG depletion in p53 mutant cancer cells after DNA damage……….……………………………………………………...114 4.2.4 Exploration of the potential gain of functions for p53 mutations that are responsible for 5-FdU resistance……………….……………………………….118 4.2.5 Identification of small molecule inhibitors of UDG via high-throughput screening.……………………………………………………………………….120 Appendix…………………………………………………………………………….….122 Reference……………………………………………………………………………….128 Page | vi LIST OF TABLES Table 1-1. Summary of uracil and 5-FU lesions repaired by mammalian DNA glycosylases…………………………….……………………………………………….14 Table 1-2. Role of downstream BER proteins in response to TS inhibitors………………18 Table 1-3. Select list of mutant p53 upregulated genes and chemoresistance…………….34 Table 3-1. Cell lines and strains used in this work…………………………….….………88 Page | vii LIST OF FIGURES Figure 1-1. Thymidylate synthesis and two classes of TS inhibitors……….…...………….5 Figure 1-2. Metabolism of fluoropyrimidines…………………….……………………….7 Figure 1-3. Base excision repair (BER) of mis-incorporated uracil (U) and 5-FU……...12 Figure 1-4. dUTPase prevents dUTP/FdUTP from incorporation into DNA during TS inhibition…………………………………………………………………………………23 Figure 1-5. Mismatch repair (MMR) of mis-incorporated 5-FU………………………….26 Figure 2-1. UDG depletion causes incorporation of uracil and 5-FU into genomic DNA by 5-FdU…………………………………………………………………………………….60 Figure 2-2. UDG depletion enhances 5-FdU sensitivity in cancer cells..............................62 Figure 2.3. Thymidine treatment after 5-FdU exposure cannot fully rescue increased cytotoxicity in UDG depleted cells……………………………………………………….64 Figure 2-4. Loss of UDG induces cell cycle arrest at late G1 and early S phase by 5-FdU exposure………………………………………………………………………………….66 Figure 2-5. UDG depletion inhibits replication fork progression following 5-FdU treatment............................................................................................................................68 Figure 2-6. DNA damage accumulates in UDG depleted cells in a caspase independent manner. …………………………………………………………….…………………….70 Page | viii Figure 3-1. 5-FdU resistance in different types of cancer cells with p53 mutation or deficiency………………………………………………………………………………...89 Figure 3-2. UDG depletion selectively sensitizes cells with p53 mutation or deficiency to 5-FdU…………………………………………………………………………………….91 Figure 3-3. 5-FdU resistance due to loss of p53 is reversed by UDG depletion…………...93 Figure 3-4. p53 knockdown re-sensitizes cancer cells with UDG depletion to 5-FdU……95 Figure 3-5. UDG depletion selectively sensitizes p53 KO cells to pemetrexed and 5- FU......................................................................................................................................97 Figure 3-6. UDG depletion induces cell death caused by 5-FdU in p53 KO cancer cells…99 Figure 4-1. Evaluation of uracil and 5-FU levels in TDG treated genomic DNA extracted following 5-FdU exposure via AP site detection assay………………………………….109 Figure 4-2: Evaluation of UDG and TDG activities via glycosylase activity assay...…...111 Figure 4-3. Synthetic sickness or lethality between DNA damage response signaling and p53………………………………………………………………………………….….117 Page | ix Appendix 1. Retention of uracil and 5-FU in HEC1A UDG depleted cells during thymidine recovery following 5-FdU exposure…………………………………………………….123 Appendix 2. Loss of UDG induces HEC1A cell cycle arrest at late G1 and early S phase following 5-FdU exposure………………………………………………………………124 Appendix 3. DNA damage accumulates in HEC1A UDG depleted cells in a caspase independent manner…………………………………………………………………….125 Appendix 4. Effect of irradiation on p21 induction in various cancer cells with different p53 status………………………………….…………………………………………….127 Page | x ACKNOWLEDGEMENTS First and foremost, it has been a privilege to have Dr. Stanton Gerson as my mentor. I would like to express my deepest gratitude for his patient guidance, immense knowledge, and gracious support throughout the course of my project and my career as a scientist. I would also like to express my sincere appreciation to my committee members, Dr. Youwei Zhang, Dr. Maria Hatzoglou, Dr. Derek Taylor, and Dr. Alexandru Almasan, for their insightful comments, hard questions, and tremendous help alongside my Ph.D. pursuit. For their encouragement, kindness, and collaboration, I would like to thank Xiangzi Han, Shuming Yang, Shashank Gorityala, Yan Xu, and the
Load more

Recommended publications
  • Thesis Was Carried out at the K
    Experimental modeling and novel therapeutic strategies in melanoma brain metastasis Terje Sundstrøm Dissertation for the degree of philosophiae doctor (PhD) University of Bergen, Norway 2015 Dissertation date: June 9th 2015 LIST OF ABBREVIATIONS 3D 3-dimensional 5-ALA 5-aminolevulinic acid AAAS American Association for the Advancement of Science ACT Adoptive cell transfer ADC Apparent diffusion coefficient AJCC American Joint Committee on Cancer AKT Protein kinase B ALK Anaplastic lymphoma kinase APC Antigen-presenting cell APOE Apolipoprotein-E ATP Adenosine triphosphate B7-H3 B7 homolog 3 BBB Blood-brain barrier BCL2A1 Bcl-2-related protein A1 bFGF Basic fibroblast growth factor BLI Bioluminescence imaging BRAF Serine/threonine-protein kinase B-raf BRMS1 Breast cancer metastasis-suppressor 1 BTB Blood-tumor barrier CI (Mitochondrial) Complex I CC22 Chemokine (C-C motif) ligand 22 CD44v6 CD44 splicing variant 6 CDK4 Cyclin-dependent kinase 4 CDKN2A p16INK4A inhibitor of CDK4 cMAP Connectivity Map CNS Central nervous system COT Serine/threonine kinase Cot CRAF RAF proto-oncogene serine/threonine-protein kinase CT Computed tomography CTLA4 Cytotoxic T-lymphocyte-associated protein 4 CXCR4 C-X-C chemokine receptor type 4 2 Da Dalton (unit) DNA Deoxyribonucleic acid DWI Diffusion weighted imaging ECM Extracranial metastases EDNRB Endothelin receptor B EFSA European Foods Safety Authority EGFR Epidermal growth factor receptor ER Estrogen receptor ERBB2 Receptor tyrosine-protein kinase erbB-2 ERK Extracellular signal-regulated kinase ET3 Endothelin-3
    [Show full text]
  • Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
    Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN-16-1901 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer Vikram B Wali1,3, Casey G Langdon2, Matthew A Held2, James T Platt1, Gauri A Patwardhan1, Anton Safonov1, Bilge Aktas1, Lajos Pusztai1,3, David F Stern2,3,Christos Hatzis1,3 1 Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA 2 Department of Pathology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA 3 Yale Cancer Center, New Haven Connecticut, USA Corresponding authors: Christos Hatzis, Ph.D. or Vikram B Wali, Ph.D. Section of Medical Oncology Yale School of Medicine Yale University 333 Cedar Street PO Box 208032 New Haven, CT 06520 [email protected] [email protected] Running Title: Novel Combination Therapies in Triple Negative Breast Cancer CONFLICTS OF INTEREST Authors have no conflict of interest to disclose. 1 Downloaded from cancerres.aacrjournals.org on October 6, 2021. © 2016 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN-16-1901 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergistic combinations tractable to clinical translation.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Mitochondrial Reprogramming in Tumor Progression and Therapy M
    Published OnlineFirst December 9, 2015; DOI: 10.1158/1078-0432.CCR-15-0460 Molecular Pathways Clinical Cancer Research Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy M. Cecilia Caino and Dario C. Altieri Abstract Small-molecule inhibitors of the phosphoinositide 3-kinase mitochondrial Hsp90s in preclinical development (gamitrinib) (PI3K), Akt, and mTOR pathway currently in the clinic produce a prevents adaptive mitochondrial reprogramming and shows paradoxical reactivation of the pathway they are intended to potent antitumor activity in vitro and in vivo. Other therapeutic suppress. Furthermore, fresh experimental evidence with PI3K strategies to target mitochondria for cancer therapy include antagonists in melanoma, glioblastoma, and prostate cancer small-molecule inhibitors of mutant isocitrate dehydrogenase shows that mitochondrial metabolism drives an elaborate process (IDH) IDH1 (AG-120) and IDH2 (AG-221), which opened new of tumor adaptation culminating with drug resistance and met- therapeutic prospects for patients with high-risk acute myelog- astatic competency. This is centered on reprogramming of mito- enous leukemia (AML). A second approach of mitochondrial chondrial functions to promote improved cell survival and to fuel therapeutics focuses on agents that elevate toxic ROS levels from the machinery of cell motility and invasion. Key players in these a leaky electron transport chain; nevertheless, the clinical expe- responses are molecular chaperones of the Hsp90 family com- rience with these compounds, including a quinone derivative, partmentalized in mitochondria, which suppress apoptosis via ARQ 501, and a copper chelator, elesclomol (STA-4783) is phosphorylation of the pore component, Cyclophilin D, and limited. In light of this evidence, we discuss how best to target enable the subcellular repositioning of active mitochondria to a resurgence of mitochondrial bioenergetics for cancer therapy.
    [Show full text]
  • RESEARCH ARTICLE Lobaplatin Combined Floxuridine/Pirarubicin
    DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.2057 The Effect Observation of LBP-based TACE for Unresectable Primary Hepatocellular Carcinoma RESEARCH ARTICLE Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma Chang Zhao1, Xu-Jie Wang2*, Song Wang2*, Wei-Hua Feng2, Lei Shi2, Chun- Peng Yu2 Abstract Purpose: To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. Patients and Methods: TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/ MRI/CT/blood routine examinations were used to evaluate short term activity and toxicity after 4-5 weeks, the process being repeated if necessary. Results: Among the 34 cases, 1 (2.9%) showed a complete response, 21 (61.7%) a partial response, 8 (23.5%) stable disease, and 4 progressive disease, with a total effective rate of 67.6%. The content of alpha fetoprotein dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status(30.4%). The median follow-up time (MFT) was 281 days (63-558 days), and median progression-free survival was 118.5 days (95%, CI:88.8-148.2days). Adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade). Conclusions: Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer. Keywords: Primary hepatic carcinoma - chemoembolization - platinum chemotherapy - clinical response Asian Pac J Cancer Prev, 15 (5), 2057-2060 Introduction LBP-based TACE, male 29 cases, female 5 cases, average age for 57.2±10.7 years, 12 cases were biopsy-proven, Hepatocellular carcinoma (HCC) is a common 22 cases were in line with the China Cancer Association malignant tumor .
    [Show full text]
  • Characterisation of Streptococcus Pneumoniae Opacity Phase Variation
    Characterisation of Streptococcus pneumoniae Opacity Phase Variation Melissa Hui Chieh Chai, BBiomedSc (Hon), MSc A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy from the University of Adelaide February 2016 Research Centre for Infectious Diseases Department of Molecular and Cellular Biology The University of Adelaide Adelaide, S.A., Australia Table of Contents Chapter 1: INTRODUCTION ........................................................................... 1 1.1 The Pneumococcus ....................................................................................................... 1 1.1.1 Burden of Disease .................................................................................................. 1 1.1.2 Antimicrobial resistance ........................................................................................ 3 1.2 Pneumococcal Vaccines ............................................................................................... 4 1.3 Pathogenesis of Pneumococcal Disease ....................................................................... 7 1.3.1 Pneumococcal colonisation.................................................................................... 7 1.3.2 Progression to disease .......................................................................................... 10 1.4 S. pneumoniae Virulence Factors ............................................................................... 11 1.4.1 Pneumococcal capsule ........................................................................................
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report
    THE NATIONAL ACADEMIES PRESS This PDF is available at http://www.nap.edu/24731 SHARE A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report DETAILS 296 pages | 6 x 9 | PAPERBACK ISBN 978-0-309-45729-3 | DOI: 10.17226/24731 CONTRIBUTORS GET THIS BOOK Gillian J. Buckley and Brian L. Strom, Editors; Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice; Health and Medicine FIND RELATED TITLES Division; National Academies of Sciences, Engineering, and Medicine Visit the National Academies Press at NAP.edu and login or register to get: – Access to free PDF downloads of thousands of scientific reports – 10% off the price of print titles – Email or social media notifications of new titles related to your interests – Special offers and discounts Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. (Request Permission) Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report Gillian J. Buckley and Brian L. Strom, Editors Committee on a National Strategy for the Elimination of Hepatitis B and C Board on Population Health and Public Health Practice Health and Medicine Division A Report of Copyright © National Academy of Sciences. All rights reserved. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW Washington, DC 20001 This activity was supported by the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, the National Viral Hepatitis Roundtable, and the U.S.
    [Show full text]
  • In Vitro and in Vivo Reversal of Resistance to 5-Fluorouracil in Colorectal Cancer Cells with a Novel Stealth Double-Liposomal Formulation
    British Journal of Cancer (2007) 97, 919 – 926 & 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00 www.bjcancer.com In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation 1 1 1 1 2 3 *,1 R Fanciullino , S Giacometti , C Mercier , C Aubert , C Blanquicett , P Piccerelle and J Ciccolini 1 2 EA3286-Laboratoire de Pharmacocine´tique, Universite´ de la Me´diterrane´e, Marseille, France; Department of Medicine, School of Medicine, Emory 3 University, Atlanta, GA, USA; Laboratoire de Pharmacie Gale´nique, Faculte´ de Pharmacie, 27 Bd Jean Moulin, Marseille 05 13385, France Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophos- phate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice.
    [Show full text]
  • Pharmacology
    Step I Pharmacology 'WSMU~ is a ~aint program 0~the lfederatlan° a"• State Meaieal Boaras a~the I!Jntitea States • lne, and the Natianal Baara a1 Medieal Examiners. USMLE·Step 1 Pharmacology Lecture Notes 2006-2007 Edition KAPLA~. I meulca • USMLE is a joint program of the Federation of State Medical Boards of the United States, Inc. and the National Board of Medical Examiners. ©2006 Kaplan, Inc. All rights reserved. No part of this book may be reproduced in any form, by photostat, microfilm, xerography or any other means, or incorporated into any information retrieval system, electronic or mechanical, without the written permission of Kaplan, Inc. Not for resale. Author Lionel P. Rayman, Pharm.D., Ph.D. Department of Pathology Forensic Toxicology Laboratory University of Miami School of Medicine Miami, FL Contributing Authors Director of Medical Curriculum Sonia Reichert, M.D. Craig Davis, Ph.D. Associate Professor Editorial Director University of South Carolina School of Medicine Department of Pharmacology, Physiology, and Neuroscience Kathlyn McGreevy Columbia, SC Production Manager Maris Victor Nora, Pharm.D., Ph.D. Michael Wolff Associate Professor Rush Medical College Production Editor Chicago.Tl. William Ng Anthony Trevor, Ph.D. Cover Design Professor Emeritus Joanna Myllo Department of Cellular and Molecular Pharmacology University of California Cover Art San Francisco, CA Christine Schaar Steven R. Harris, Ph.D. Associate Dean for Basic Sciences Associate Professor of Pharmacology Pikeville College School of Osteopathic Medicine
    [Show full text]
  • Key Enzymes in Cancer: Mechanism of Action and Inhibition with Anticancer Agents
    University of Texas Rio Grande Valley ScholarWorks @ UTRGV Chemistry Faculty Publications and Presentations College of Sciences 2018 Key Enzymes in Cancer: Mechanism of Action and Inhibition With Anticancer Agents Debasish Bandyopadhyay The University of Texas Rio Grande Valley, [email protected] Gabriel Lopez The University of Texas Rio Grande Valley Stephanie Cantu The University of Texas Rio Grande Valley Samantha Balboa The University of Texas Rio Grande Valley Annabel Garcia The University of Texas Rio Grande Valley See next page for additional authors Follow this and additional works at: https://scholarworks.utrgv.edu/chem_fac Part of the Chemistry Commons, and the Life Sciences Commons Recommended Citation Debasish Bandyopadhyay, Gabriel Lopez, Stephanie Cantu, Samantha Balboa, Annabel Garcia, Christina Silva, Diandra Valdes. In Chemistry Research and Applications (Vol. 2): Organic and Medicinal Chemistry, Chapter 9; Key Enzymes in Cancer: Mechanism of Action and Inhibition with Anticancer Agents. 2018, Nova Science Publishers, Inc., Hauppauge, New York, USA (ISBN: 978-1-53614-855-8). This Book is brought to you for free and open access by the College of Sciences at ScholarWorks @ UTRGV. It has been accepted for inclusion in Chemistry Faculty Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [email protected], [email protected]. Authors Debasish Bandyopadhyay, Gabriel Lopez, Stephanie Cantu, Samantha Balboa, Annabel Garcia, Christina Silva, and Diandra Valdes This book is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/chem_fac/131 In: Organic and Medicinal Chemistry, Volume 2 ISBN: 978-1-53614-855-8 Editor: Bimal Krishna Banik © 2019 Nova Science Publishers, Inc.
    [Show full text]
  • Gene Regulatory Network Analysis with Drug Sensitivity Reveals Synergistic
    www.nature.com/scientificreports OPEN Gene regulatory network analysis with drug sensitivity reveals synergistic efects of combinatory chemotherapy in gastric cancer Jeong Hoon Lee1, Yu Rang Park 2, Minsun Jung 3 & Sun Gyo Lim 4* The combination of docetaxel, cisplatin, and fuorouracil (DCF) is highly synergistic in advanced gastric cancer. We aimed to explain these synergistic efects at the molecular level. Thus, we constructed a weighted correlation network using the diferentially expressed genes between Stage I and IV gastric cancer based on The Cancer Genome Atlas (TCGA), and three modules were derived. Next, we investigated the correlation between the eigengene of the expression of the gene network modules and the chemotherapeutic drug response to DCF from the Genomics of Drug Sensitivity in Cancer (GDSC) database. The three modules were associated with functions related to cell migration, angiogenesis, and the immune response. The eigengenes of the three modules had a high correlation with DCF (−0.41, −0.40, and −0.15). The eigengenes of the three modules tended to increase as the stage increased. Advanced gastric cancer was afected by the interaction the among modules with three functions, namely cell migration, angiogenesis, and the immune response, all of which are related to metastasis. The weighted correlation network analysis model proved the complementary efects of DCF at the molecular level and thus, could be used as a unique methodology to determine the optimal combination of chemotherapy drugs for patients with gastric cancer. Although its incidence is decreasing in some parts of the world, gastric cancer is still the fourth most common cancer worldwide1,2.
    [Show full text]